Anti-Mouse/Human GL7 – Purified No Carrier Protein

LPS activated DBA/J mouse B cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

ELISA,
FC,
IHC,
IP,
MACS,
WB

GL7 (aka Ly77) is an antiglycan antibody that recognizes α2,6-linked Sia-containing glycan chains found on N-glycans of various proteins.

GL7 antibody was originally used in mouse to identify a 35 kDa cell surface protein expressed selectively on subpopulations of activated B and T cells as well as discrete subpopulations of T and B lineage cells in vivo 1GL7 antibody was originally used in mouse to identify a 35 kDa cell surface protein expressed selectively on subpopulations of activated B and T cells as well as discrete subpopulations of T and B lineage cells in vivo¹. GL7 recognizes a glycan moiety containing a terminal sialic acid (Sia)². Determinant recognition by GL7 is specific to Neu5Ac-bearing glycans, which is a Sia modification at the C-5 position.

GL7 reactivity has been assessed against various mouse and human B cell lines². In mouse bone marrow, GL7 first appears on the cell surface of B220⁺CD117⁺ pro-B cells and then peaks at the B220⁺CD40^- pro-B/pre-B-I transition, with expression decreasing slightly after the pre-B-I phase^3,4. GL7 expression remains high on pre-B-II and immature B cells but is almost completely downregulated on mature B cells³. This phenotype is independent of mouse genetic background. In contrast, thymic GL7 expression differs between BALB/c and C57BL/6 strains⁵.

GL7 has stronger reactivity against human B cell lines than mouse B cell lines². Staining patterns show that the GL7 epitope on Daudi cells is similar to that of mouse activated B cells and is inhibited by broad sialidase treatment but not treatment specific to α2,3-linked Sia. Differences in GL7 epitope expression, caused by differential expression of enzymes involved in the biosynthesis of the GL7 epitope glycan, rather than differences in carrier protein expression, leads to variable staining in human B cell lines. ST6GAL1 has the strongest correlation with the GL7 staining profile.

GL7 binds to cell surface proteins expressed selectively on subpopulations of activated mouse B cells, CD4⁺, and CD8⁺ T cells as well as germinal centers in KLH immunized spleen or lymph nodes. GL7 also binds some thymocytes (CD4⁺CD8^-) and B220⁺ cells as well as large pre-B cells in bone marrow. Additionally, GL7 is expressed on germinal center B cells, some neuronal cell types, choroid plexus epithelial cells, and some B cells derived from spleen, lymph node, peritoneal cavity, liver, and peripheral blood.

Neu5Ac-recognizing lectins

1.Laszlo G, Hathcock KS, Dickler HB, et al. J Immunol.150(12):5252-5262. 1993.
2 Naito Y, Takematsu H, Koyama S, et al. Mol Cell Biol. 27(8):3008-3022. 2007.
3 Cervenak L, Magyar A, Boja R, et al. Immunol Lett. 78(2):89-96. 2001.
4 Murasawa M, Okada S, Obata S, et al. Eur J Immunol. 32(1):291-298. 2002.
5 Hathcock KS, Pucillo CE, Laszlo G, et al. J Immunol. 155(10):4575-4581. 1995.